Kala Pharmaceuticals, Inc. Announces Launch of INVELTYS
January 07, 2019 at 12:00 pm
Share
Kala Pharmaceuticals, Inc. announced the launch of INVELTYS (loteprednol etabonate ophthalmic suspension) 1%, the first and only twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. INVELTYS is now in national and regional United States (U.S.) pharmaceutical distribution centers, and patients have access to INVELTYS through their local retail pharmacies. INVELTYS was approved in August 2018 as the first and only twice-daily ocular corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. INVELTYS utilizes Kala’s proprietary AMPPLIFY Drug Delivery Technology to enhance penetration into target tissues of the eye. In preclinical studies, the AMPPLIFY technology increased delivery of loteprednol etabonate (LE) into ocular tissues more than three-fold compared to current LE products by facilitating penetration through the tear film mucins. The AMPPLIFY technology also underpins KPI-121 0.25%, a product candidate for the temporary relief of signs and symptoms of dry eye disease utilizing a two-week course of therapy.
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development and commercialization of therapies for rare and severe diseases of the eye. The Companyâs biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Companyâs product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived bio factors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its KPI-012 is used for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
KALA BIO, INC. 
